Gina Bevando
Acute Care · Simi Valley, CANPI 1245896257
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 395 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,826 and has fallen 61.7% since, to $699 in 2025. Among acute care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 395 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Gilead$956
- QOL Medical, LLC$647
- Johnson & Johnson$464
- Ardelyx, Inc.$363
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,74597%
- Education$2323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 103 | $1,428 |
| AbbVie | 59 | $1,083 |
| Gilead | 75 | $956 |
| QOL Medical, LLC | 28 | $647 |
| Johnson & Johnson | 15 | $464 |
| Ardelyx, Inc. | 17 | $363 |
| Regeneron Healthcare Solutions, Inc. | 13 | $299 |
| Lilly USA, LLC | 14 | $271 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $269 |
| Bristol Myers Squibb | 10 | $175 |
| Sanofi | 5 | $121 |
| Vivus LLC | 6 | $107 |
| Ferring Pharmaceuticals Inc. | 6 | $104 |
| Evoke Pharma, Inc. | 4 | $79 |
| Intercept Pharmaceuticals, Inc. | 4 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $69 |
| Merck | 3 | $59 |
| Lucid Diagnostics Inc. | 3 | $55 |
| Endogastric Solutions, Inc | 1 | $54 |
| Pfizer | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $27 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Echosens North America, Inc. | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Celltrion USA Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
How this compares
$6,977 in reported general payments places this provider in the 95th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 14 | $164,148 |
| CreonLipase/Protease/Amylase | 46 | $143,132 |
| IbsrelaTenapanor Hcl | 18 | $43,749 |
| RelistorMethylnaltrexone Bromide | 16 | $37,066 |
| LinzessLinaclotide | 11 | $10,002 |
| Pantoprazole Sodium | 480 | $9,338 |
| Mesalamine | 32 | $8,645 |
| Mesalamine ErMesalamine | 20 | $7,807 |
| MovantikNaloxegol Oxalate | 15 | $7,295 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 112 | $6,872 |
| Dexlansoprazole DrDexlansoprazole | 16 | $3,909 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 20 | $3,265 |
| Sucralfate | 60 | $2,724 |
| Omeprazole | 120 | $1,479 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $647 | $164,14814 claims |
| AbbVieCreon, Linzess | $1,083 | $153,13457 claims |
| Ardelyx, Inc.Ibsrela | $363 | $43,74918 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,428 | $37,06616 claims |
| Redhill Biopharma Inc.Movantik | $14 | $7,29515 claims |
| Braintree Laboratories, Inc.Sutab | $14 | $3,26520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,153 acute care providers in California.
Other acute care in Simi Valley
- Leslie PetersenCamarillo$370K
- Joyce KhremianSan Dimas$73K
- Eleanor VierraSacramento$64K
- Frances DyLos Angeles$57K
- Savannah HarrisVentura$56K
- Kori Ann JohnstonLos Angeles$42K
- Caroline KwongOrange$42K
- Gregory KnutzenColton$41K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.